WillItSurvive
Medical technology and health companies · United States

Evolent Health

evolenthealth.com ↗

Evolent manages specialty care and prior authorization for health plans covering 21 million lives.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: Q2 2026 earnings, tracking Performance Suite MER trend and national payer expansion revenue
The call

Evolent still holds the client relationships and delegation rights big payers need, but its core risk bearing contracts are losing money faster than new business can offset it.

Evolent Health runs medical review and care management services for health insurance companies and employers, handling decisions about whether treatments get approved. It is hard to build from scratch because Evolent has contracts with many payers, embedded workflows, and regulatory approvals, but this advantage is eroding fast. UnitedHealth and Carelon (owned by Elevance) are larger competitors undercutting prices, while new AI companies like Cohere Health and GenHealth are automating the approval work that Evolent charges for, meaning fewer approvals need human review. Even Evolent's own AI tools are shrinking the fees it can collect. The critical question is whether Evolent can expand to more national payers and stabilize its unit economics (the profit per customer) in the next few quarters, or whether the business keeps bleeding money as AI keeps automating its core work.

Why
01
AI pressure: Cohere Health, GenHealth, CMS WISeR AI pilot. AI vendors now ship 90%+ first-pass prior auth approvals, the exact workflow Evolent charges payers to run. Could AI do the core job? Only partly.
02
Bigger players: UnitedHealth/Optum and Elevance/Carelon. Optum and Carelon run the same specialty care management in house and can underprice Evolent to keep clients captive. Could a giant copy it? Probably.
03
What protects it. Payer-agnostic delegation status and embedded utilization management workflows across health plans that would need years to rebuild in house.
What would change this call
Q2 2026 earnings (~August 2026) Performance Suite MER stays above 90%. Shows the core risk-bearing specialty care model is still bleeding, not stabilizing.
CMS WISeR AI prior-auth pilot expands beyond six states into Medicare Advantage routing. Would show government is redirecting prior-auth workflow away from delegated vendors like Evolent.
National payer expansion fails to reach announced $200M annualized revenue target in H2 2026. Would show payers are not renewing trust in Evolent's delegated model despite its scale.
Key numbers
  • Performance Suite MER hit 93.3% in Q1 2026, up from 84% (2026-05-07)
  • Net loss widened to $579.4 million in 2025 from $93.5 million (2026-02-24)
  • Net debt near $792 million versus market cap around $660 million (2026-05-08)
Named risks
  • Securities litigation over August 2025 guidance cut remains unresolved. Severity: high
  • Net debt of ~$792M versus market cap near $658-669M as of mid-2026. Severity: high
  • Performance Suite MER deterioration (84% to 93.3% YoY) squeezing margins. Severity: high
  • State AI-in-utilization-management laws (California, Colorado, NJ) raise compliance costs. Severity: medium
  • Headcount decline and January 2026 layoffs signal ongoing cost-cutting pressure. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
UnitedHealth/OptumcontestingPayer-owned scale rival; Evolent positions as neutral alternative as of 2026-03
Elevance Health/CareloncontestingDirect captive competitor leveraging Blue Cross client base, cited 2026-03-20
Cohere Health / GenHealth (AI-native prior-auth vendors)gaining onReporting 90%+ first-pass prior-auth approvals industry-wide by 2026-06
CMS WISeR AI prior-auth pilotgaining onGovernment AI pilot running in six states as of 2026-03
Privia Healthgaining onAcquired Evolent's ACO business Sept 2025, expanding to ~1.5M attributed lives
Questions people ask
Is Evolent Health profitable in 2026?
No. Evolent posted a $579.4 million net loss for full-year 2025, up sharply from a $93.5 million loss in 2024. Its Performance Suite medical expense ratio hit 93.3% in Q1 2026, versus 84.0% a year earlier, signaling continued margin pressure into 2026 (reported 2026-05-07).
Is Evolent Health laying off employees?
Yes. Chicago Business reported Evolent planning layoffs as of January 19, 2026. Headcount fell from about 4,489 in 2023 to roughly 3,940 by December 2025, a cumulative ~12% decline, with active job postings down 60% year-over-year in 2025.
Could AI replace Evolent Health's prior authorization business?
AI is a live threat: CMS is piloting an AI prior-authorization model (WISeR) in six states, and vendors like Cohere Health and GenHealth target the same utilization-management workflow Evolent monetizes. Evolent counters with delegated regulatory status and payer contracts, and reports internal AI auto-approvals up to 30% (as of 2026-05-08).
Who is Evolent Health's biggest competitor?
Elevance Health's Carelon is a direct captive rival using its own Blue Cross client base, while UnitedHealth's Optum represents the payer-owned scale threat Evolent positions against as a 'neutral' vendor. AI-native prior-auth startups are also contesting its core workflow as of mid-2026.
Who owns Evolent Health?
Evolent Health is an independent public company trading on NYSE under ticker EVH, with no parent company as of mid-2026. Reuters reported it was in talks with private equity firms about a potential sale in August 2024, but no deal had been announced as of September 2025.
Is Evolent Health being acquired?
Unconfirmed. Reports surfaced in August 2024 that Evolent was in talks with private equity firms and healthcare services providers about a sale, but as of September 2025 no transaction had been announced, and the company instead pursued a divestiture and debt restructuring.
Timeline
  • 2026-07-21Q1 2026 revenue of $496.2M missed consensus by ~7%; FY2026 guidance reaffirmed
  • 2026-05-07Performance Suite MER hit 93.3% in Q1 2026, up from 84.0% a year earlier
  • 2026-05-01Evolent began managing oncology prior-authorization review for Highmark members
  • 2026-01-19Evolent reported plans for layoffs alongside State Farm, per Chicago Business
  • 2026-01-01Mario Ramos, ex-CVS Caremark CFO, became Evolent's CFO
  • 2025-09-23Divested Evolent Care Partners (ACO business) to Privia Health for up to $113M
  • 2025-08-08Guidance cut after weak Q2 2025 revenue triggered securities litigation investigations
  • 2025-08Issued $145M convertible senior notes due 2031 and exchanged $175M preferred stock for debt
  • 2024-08Reuters reported Evolent in talks with private equity firms about a potential sale
  • 2015Evolent Health went public on NYSE, raising $195 million in its IPO
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources